A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Beckman Symposium Bookmark and Share

The 24th Beckman Symposium - New Horizons on Oncogenesis

Date
Friday, November 14, 2014
8:45 a.m. to 5:30 p.m.

Location
City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

Overview
The 24th Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
 
 
2014 Speaker List:
 
Joe Gray, Ph.D.,
Knight Cancer Institute, University of Oregon Health and Science University
 
Edward T.H. Yeh, M.D.,
University of Texas MD Anderson Cancer Center
 
Iannis Aifantis, Ph.D.,
Howard Hughes Medical Institute and NYU School of Medicine
 
Valerie Weaver, Ph.D.,
University of California, San Francisco
 
Channing Der, Ph.D.,
Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
Dafna Bar-Sagi, Ph.D.,
NYU Langone Medical Center
 
David Cheresh, Ph.D.,
Moores Cancer Center, University of California,  San Diego

 

In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.

 

2014 Symposium Program

8:15 to 8:45 a.m.
Registration
 
8:50 to 9:00 a.m.
Welcome, Steven Rosen, M.D., Provost, City of Hope
 
9:00 to 10:00 a.m.
Spatial Systems Biology of Cancer
Joe Gray, Ph.D., Knight Cancer Institute, University of Oregon Health and Science University
 
10:00 to 10:15 a.m.
Break
 
10:15 to 11:15 a.m.
Doxorubicin-induced Cardiotoxicity: SUMO, Ubiquitin, and Topoisomerase 2b
Edward T.H. Yeh, M.D., University of Texas MD Anderson Cancer Center
 
11:15 a.m. to 12:15 p.m.
Epigenetic Regulation of Acute Leukemia Initiation and Progression Iannis Aifantis, Ph.D., Howard Hughes Medical Institute and NYU School of Medicine
 
12:15 to 1:15 p.m.
Lunch
 
1:15 to 2:15 p.m.
Tissue Force, Tumor Progression and Treatment
Valerie Weaver, Ph.D., University of California, San Francisco
 
2:15 to 3:15 p.m.
Drugging the Undruggable Ras: Mission Possible?
Channing Der, Ph.D., Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
3:15 to 3:30 p.m.
Break
 
3:30 to 4:30 p.m.
Oncogenic Ras Signaling: From Biology to Therapeutics
Dafna Bar-Sagi, Ph.D., NYU Langone Medical Center
 
4:30 to 5:30 p.m.
A β3 Integrin-KRAS-RalB Complex Drives Tumor Stemness and Resistance to EGFR Inhibition
David Cheresh, Ph.D., Moores Cancer Center, University of California,  San Diego

Beckman Symposium

The 24th Beckman Symposium - New Horizons on Oncogenesis

Date
Friday, November 14, 2014
8:45 a.m. to 5:30 p.m.

Location
City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

Overview
The 24th Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
 
 
2014 Speaker List:
 
Joe Gray, Ph.D.,
Knight Cancer Institute, University of Oregon Health and Science University
 
Edward T.H. Yeh, M.D.,
University of Texas MD Anderson Cancer Center
 
Iannis Aifantis, Ph.D.,
Howard Hughes Medical Institute and NYU School of Medicine
 
Valerie Weaver, Ph.D.,
University of California, San Francisco
 
Channing Der, Ph.D.,
Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
Dafna Bar-Sagi, Ph.D.,
NYU Langone Medical Center
 
David Cheresh, Ph.D.,
Moores Cancer Center, University of California,  San Diego

 

In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.

 

Symposium Program

2014 Symposium Program

8:15 to 8:45 a.m.
Registration
 
8:50 to 9:00 a.m.
Welcome, Steven Rosen, M.D., Provost, City of Hope
 
9:00 to 10:00 a.m.
Spatial Systems Biology of Cancer
Joe Gray, Ph.D., Knight Cancer Institute, University of Oregon Health and Science University
 
10:00 to 10:15 a.m.
Break
 
10:15 to 11:15 a.m.
Doxorubicin-induced Cardiotoxicity: SUMO, Ubiquitin, and Topoisomerase 2b
Edward T.H. Yeh, M.D., University of Texas MD Anderson Cancer Center
 
11:15 a.m. to 12:15 p.m.
Epigenetic Regulation of Acute Leukemia Initiation and Progression Iannis Aifantis, Ph.D., Howard Hughes Medical Institute and NYU School of Medicine
 
12:15 to 1:15 p.m.
Lunch
 
1:15 to 2:15 p.m.
Tissue Force, Tumor Progression and Treatment
Valerie Weaver, Ph.D., University of California, San Francisco
 
2:15 to 3:15 p.m.
Drugging the Undruggable Ras: Mission Possible?
Channing Der, Ph.D., Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
3:15 to 3:30 p.m.
Break
 
3:30 to 4:30 p.m.
Oncogenic Ras Signaling: From Biology to Therapeutics
Dafna Bar-Sagi, Ph.D., NYU Langone Medical Center
 
4:30 to 5:30 p.m.
A β3 Integrin-KRAS-RalB Complex Drives Tumor Stemness and Resistance to EGFR Inhibition
David Cheresh, Ph.D., Moores Cancer Center, University of California,  San Diego
Research Overview
City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.

Beckman Research Institute

Beckman Research Institute of City of Hope is internationally  recognized for its innovative translational biomedical research.
 

Comprehensive Cancer Center
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and education.

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Technology & Licensing
The Center for Applied Technology Development offers broad expertise in
technology transfer and licensing, biologics manufacturing, quality assurance and regulatory affairs.

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 



NEWS & UPDATES
  • Frank Di Bella, 70, is on a mission: Find a cure for metastatic bladder cancer. It’s just possible he might. Although Di Bella isn’t a world-renowned physician, cancer researcher or scientist, he knows how to make things happen. For more than 20 years, he served as chairman of annual fundraising gal...
  • The physical side effects of cancer can damage anyone’s self-confidence, but especially that of women who, rightly or wrongly, are more likely to find their appearance (or their own perception of their appearance) directly connected to their ability to face the world with something resembling aplomb. Furt...
  • The promise of stem cell therapy has long been studied in laboratories. Now, as medicine enters an era in which this therapy will be increasingly available to patients, the nurses who help deliver it will be in the spotlight. City of Hope, which has launched its Alpha Clinic for Cell Therapy and Innovation (ACT...
  • Just because you can treat a condition, such as high cholesterol, at the end of life — well, that doesn’t mean you should. That’s the basic lesson of a study to be published March 30 in JAMA Internal Medicine. The ramifications go far beyond that. The research, in which City of Hope’s Betty Fe...
  • The understanding of the relationship between genetics and cancer risk continues to grow, with more genetic testing than ever before available to patients. However, the adage that a little knowledge is a dangerous thing is applicable: Without context for what a test result means, and without meaningful guidance...
  • Standard prostate biopsies haven’t changed significantly in the past 30 years – nor have the problems inherent with them. Regular biopsies have an expected error rate: Tumors may potentially be undersampled and, 30 percent of the time, men who undergo a radical prostatectomy are found to have more aggress...
  • In the field of cancer, patients have had surgery, chemotherapy and radiation therapy as options. Now, as City of Hope officially opens the Alpha Clinic for Cellular Therapy and Innovation, patients battling cancer and other life-threatening diseases have another option: stem-cell-based therapy. The Alpha Clini...
  • How does the environment affect our health? Specifically, how does it affect our risk of cancer? City of Hope physicians and researchers recently answered those questions in an Ask the Experts event in Corona, California, explaining the underlying facts about how the environment can affect our health. Moderator...
  • Nurses and other medical professionals have come to understand that it’s not enough just to fight disease. They also must provide pain relief, symptom control, and an unrelenting commitment to improve patients’ quality of life — especially at the end of life. Not too long ago, this was a relatively ...
  • “Tonight, I’m launching a new precision medicine initiative to bring us closer to curing diseases like cancer.” These were the words of President Barack Obama on Jan. 20, 2015, during his State of the Union address. So what is precision medicine, and how close are we to making it a reality for...
  • March is Colon Cancer Awareness Month. How sad, yet how serendipitous, that the co-creator of “The Simpsons” Sam Simon passed away in March after a four-year battle against colon cancer. What message can we all learn from his illness that can help us prevent and overcome colon cancer in our own lives? Colon can...
  • Misagh Karimi, M.D., assistant clinical professor, is a medical oncologist at one of City of Hope’s newest community practice locations, located in Corona in Riverside County. A recent community health report from Corona’s public health department stated that obesity rates for teens and adults in Riverside Coun...
  • In 1975, the median survival for patients with ovarian cancer was about 12 months. Today, the median survival is more than 5 years. Although researchers and clinicians are far from satisfied, the progress in ovarian cancer treatment is encouraging, said Robert Morgan, M.D., F.A.C.P., professor of medical oncolo...
  • Colorectal cancer may be one of the most common cancers in both men and women, but it’s also one of the most curable cancers. Today, because of effective screening tests and more advanced treatment options, there are more than 1 million survivors of colorectal cancer in the United States. Here, colorectal...
  • Breast cancer treatment can damage a woman’s ability to become pregnant, making the impact on fertility one of the key factors that many consider when choosing a therapy regimen. Now a study has found that breast cancer patients treated with a hormone-blocking drug in addition to chemotherapy were less li...